Voyager Therapeutics, Inc. (VYGR)
VYGRNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$1.73
+0.0300 (+1.76%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $107.66m
- P/E
- –
- EPS, last 4 quarters
- $-1.73
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.67 to $5.48
- Average volume
- –
- Previous close
- $1.70
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $13.40, +674.6% from here
Earnings
next estimate $-0.3400Next report
Dec 2025
+14.8%
Mar 2026
+13.0%
Jun 2026
+27.3%
Sep 2026
+2.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $15.34m | $2.59m | $3.17m | $4.01m |
| Gross profit | $15.34m | $2.59m | $3.17m | $4.01m |
| Operating income | -$29.93m | -$30.27m | -$26.39m | -$26.42m |
| Net income | -$27.43m | -$27.94m | -$24.47m | -$24.69m |
Last four quarters: revenue $25.11m, margin -416.3%, free cash flow –
News
8 latest- Voyager Therapeutics Reports Third Quarter 2026 Financial Results and $132 Million Cash PositionFintel · Nov 6, 2026
- Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue EstimatesZacks · Nov 5, 2026
- Voyager Therapeutics, Inc. Appoints Robin Swartz as President and Outlines CEO Succession PlanFintel · Oct 21, 2026
- Voyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock Down RTTNews · Oct 21, 2026
- FDA Clears Voyager's IND For VY1706 In Alzheimer's Disease; Plans Trial Dosing In H2 2026 RTTNews · Jun 2, 2026
- Voyager's VY1706 Cuts Tau In Single Dose; Alzheimer's Trial Set For H2 2026 RTTNews · May 13, 2026
- Voyager Therapeutics (VYGR) Price Target Increased by 12.22% to 17.17Fintel · Mar 27, 2026
- Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesZacks · Mar 9, 2026
The company
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of - and ultimately cure - neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- voyagertherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.